Avidity
Gavin Dawson, MBA, is an experienced executive in analytics and commercial strategy within the biopharmaceutical industry, currently serving as Executive Director of Insights, Analytics and Forecasting at Avidity Biosciences, Inc. since June 2025, where responsibilities include leading analytics, market research, and forecasting efforts for late-stage neuromuscular assets. Prior to this role, Dawson held significant positions at Madrigal Pharmaceuticals from June 2021 to June 2025, including Executive Director of Commercial Strategy and Analytics and other leadership roles focused on data strategy and analytics. Previous experience spans multiple organizations, including TRINITY, Xeris Pharmaceuticals, Neurocrine Biosciences, Circassia, and United Therapeutics, with a proven track record in commercial operations, sales analytics, and global data operations. Dawson holds an MBA in Business Analytics from the American University - Kogod School of Business and a Bachelor of Business Administration in Marketing from the University of North Carolina at Charlotte.
This person is not in any teams
This person is not in any offices
Avidity
2 followers
Avidity Biosciences is pioneering a new class of precision medicines – antibody-siRNA conjugates (ASC™) – to deliver nucleic acid therapeutics against genetic drivers of disease. Our ASCs have drug-like properties similar to antibodies and antibody-drug conjugates. Importantly, their unique siRNA-based “payloads” permit selective targeting of disease-associated mRNAs against virtually any target of interest.